Evaluation of the biological behavior of ACTH-secreting pituitary tumors using various methods

Close metadata

This literature review is aimed at studying markers obtained by various research methods to assess the biological behavior of ACTH-secreting pituitary tumors. This paper presents the clinical, laboratory, instrumental, histological, and immunohistochemical aspects of ACTH-secreting pituitary tumors. Histological method allows assessing the structures of a tumor and differential diagnosis of other pathological processes in the sella turcica. Immunohistochemical method enables determining the expression of multiple markers (fibroblast growth factors, matrix metalloproteinases, apoptotic factors, pituitary tumor transforming gene, and vascular markers), which reflect various processes of oncogenesis of studied tumors, and, according to the authors, are promising with regard to predicting biological behavior using corticotropin. Epigenetic investigations including the study of micro-RNA expression, proteomics, and transcriptomics are the new methods in this area, which are expected to provide additional details regarding the prediction using corticotropin. Thus, the cumulative assessment using laboratory and instrumental methods, the study of immunoexpression of malignant potential markers in the tissue using corticotropin and micro-RNA allow predicting the future biological behavior of ACTH-secreting pituitary tumors.

Keywords:

ACTH-secreting pituitary tumor

evaluation and markers of malignant potential

Authors:

Lapshina A.M.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Marova E.I.

Endocrinology Research Centrer

List of references:

Vaks V. Clinical neuroendocrinology. Edited by Acad. of the Russian Academy of Sciences and Academy of Medical Sciences Dedov I. Moscow: UP-PRINT; 2011:7-27. (In Russ.).
Monson JP. The epidemiology of endocrine tumors. Endocrine Related Cancer. 2000;7:29-36. doi: 10.1677/erc.0.0070029.
Marova E.I. Clinical neuroendocrinology. Moscow: UP-PRINT; 2011: 51 -78. (In Russ.).
Vorontsova A.V. Clinical neuroendocrinology. Moscow: UP-PRINT; 2011:39-50. (In Russ.).
Trouillas JRP, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathologica. 2013;126:123-135. doi: 10.1007/s00401-013-1084-y.
Raverot G, Jouanneau E, Trouillas J. Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. European Journal of Endocrinology. 2014;170:R121-R132. doi: 10.1530/EJE-13-1031.
Saeger W, Lü DK, Buchfelder M, Fahlbusch R, Quabbe H-J, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. European Journal of Endocrinology. 2007;156:203-216.
DeLellis RA, Lloyd RV, Heitz PU, Eng C. (eds). World Health Organization Classification of tumours. Pathology and genetics of tumours of endocrine organs. IARC Press. Lyon. 2004;27.
Asa SL. Tumors of the Pituitary Gland. Fascicle 15, 4th Series. The Atlas of Tumor Pathology. Armed Forces Institute of Pathology. 2011;340-350. Washington DC.
Mete O, Asa SL. Clinicopathological Correlations in Pituitary Adenomas. Brain Pathology. 2012;22:443-453. doi:10.111/j.1750-3639.2012.00599.x.
George DH, Scheithauer BW, Kovacs K, Horvath E, Young WFJr, Lloyd RV, Meyer FB. Crooke’s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol. 2003;27:1330-1336.
Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W. Silent adenoma subtype 3 of the pituitary-immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol. 2005;29:511-524.
Al-Brahim NY, Asa SL. My approach to pathology of the pituitary gland. J Clin Pathol. 2006;59:1245-1253.
Asa SL. Practical pituitary pathology: what does the pathologist need to know? Arch Pathol Lab Med. 2008;132:1231-1240.
Zada G, Woodmansee WW, Ramkissoon Sh, Amadio J, Nose V, Laws REJr. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg. 2011;114:336-344. doi: 10.3171/2010.8.JNS10290.
Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv. 2006;449:395-401.
Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J, Pugeat M, Trouillas J. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing’s disease. European Journal of Endocrinology. 2010;163:35-43. doi: 10.1210/jc.2009-1191.
Dudziak K, Honegger J, Bornemann A, Horger M, Mussig K. Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course - case report and review of the literature. Journal of Clinical Endocrinology and Metabolism. 2011;96:2665-2669. doi: 10.1210/jc.2011-1166.
Heaney AP. Pituitary Carcinoma: Difficult Diagnosis and Treatment. J Clin Endocrinol Metab. 2011;96(12):3649-3660. doi: 10.1210/jc.2011-2031.
Ozgur M, Ezzat Sh, Asa SL. Biomarkers of aggressive pituitary adenomas. Journal of Molecular Endocrinology. 2012;49:69-78. doi: 10.1530/JME-12-0113.
Gong J, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Lopes MB, Hussaini IM, Laws ER. Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary. 2008;11:37-48. doi: 10.1007/s11102-007-0066-2.
Hussaini IM, Trotter C, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Agi CU, Redpath GT, Fang Z, Leung GK, et al. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. American Journal of Pathology. 2007;170:356-365. doi: 10.2353/ajpath.2007.060736.
Liu W, Matsumoto Y, Okada M, Miyake K, Kunishio K, Kawai N, Tamiya T, Nagao S. Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. Journal of Medical Investigation. 2005;52:151-158.
Tanase CP, Ogrezeanu I, Badiu C. Apoptosis (chapter 5), MicroRNAs (chapter 8), New Generic Tools for Diagnosis: Genomics and Proteomics (chapter 9) in Molecular Pathology of Pituitary Adenomas. Elsevier, London 2012;45-52, 92-96, 98-106.
Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324-1337. doi:10.1038/sj.onc.1210220.
Han L, Wu C, Riaz H, et al. Characterization of the mechanism of inhibin α-subunit gene in mouse anterior pituitary cells by RNA interference. PLoS One. 2013;8(10):e74596. doi:10.1371/journal.pone.0074596.
Nagy Z, Gatter KC, Esiri MM, Wass JA, Harris AL. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour. Br J Cancer. 2000;82(8):1441-1445. doi:10.1054/bjoc.1999.1074.
Tanase C, Albulescu R, Codrici E, Calenic B, Popescu ID, Mihai S, Necula L, Cruceru ML, Hinescu ME. Decreased expression of APAF-1 and increased expression of cathepsin B in invasive pituitary adenoma. OncoTargets and Therapy. 2015;8:81-90.
Jankowska A, Wasko R, Waligorska-Stachura J, et al. Survivin products in pituitary tumors. Neuro Endocrinol Lett. 2008;29(6):1033-1037.
Zhang YC, Gao J, Xin T, Zheng ZM, Teng LZ. Expression of survivin in invasive pituitary adenoma. Saudi Med J. 2008;29(11):1589-1592.
Salehi F, Kalman K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocrine Related Cancer. 2008;15:721-743. doi: 10.1677/ERC-08-0012.
Saez C, Japon MA, Ramos-Morales F, Romero F, Segura DI, Tortolero M, Pintor-Toro JA. PTTG is overexpressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene. 1999;18:5473-5476.
Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism. 1999a;84:761-767.
Zhang X, Horwitz GA, Prezant TR,Valentini A, Nakashima M, Bronstein MD, Melmed S. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Molecular Endocrinology. 1999b;13:156-166.
Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montange M, Rey C, Figarella-Branger D, et al. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocrine Related Cancer. 2007;14:887-900. doi:10.1677/ERC-07-0062.
Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clinical Endocrinology. 2006;65:536-543. doi: 10.1111/j.1365-2265.2006.02630.x.
Hunter JA, Skelly RH, Aylwin SJ, Geddes JF, Evanson J, Besser GM, Monson JP, Burrin JM. The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. European Journal of Endocrinology. 2003;148:203-211. doi: 10.1530/eje.0.1480203.
Han L, Wu C, Riaz H, et al. Characterization of the mechanism of inhibin α-subunit gene in mouse anterior pituitary cells by RNA interference. PLoS One. 2013;8(10):e74596.
McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. Journal of Clinical Endocrinology and Metabolism. 2002;87:4238-4244. doi: http://dx.doi.org/10.1210/jc.2002-020309.
McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA, et al. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clinical Endocrinology. 2003;58:141-150. doi: 10.1046/j.1365-2265.2003.01598.x.
Minematsu T, Suzuki M, Sanno N, Takekoshi S, Teramoto A, Osamura RY. PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocrine Pathology. 2006;17:143-153.
Heaney AP, Fernando M, Melmed S. Functional role of estrogen in pituitary tumor pathogenesis. Journal of Clinical Investigation. 2002;109:277-283. doi: 10.1172/JCI14264.
Amaral FC, Torres N, Saggioro F, Neder L, Machado HR, Silva WAJr, Moreira AC, Castro M. MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. Journal of Clinical Endocrinology and Metabolism. 2009;94:320-323.
Tahir A, Chahal HS, Korbonits M. Molecular genetics of the AIP gene in familial pituitary tumorigenesis. Progress in Brain Research. 2010;182:229-253. doi: 10.1016/S0079-6123(10)82010-2.
Wierinckx A, Roche M, Raverot G, Legras-Lachuer C, Croze S, Nazaret N, Rey C, Auger C, Jouanneau E, Chanson P, et al. Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathology. 2011;21:533-543. doi: 10.1111/j.1750-3639.2011.00476.x.
Bottoni A, Piccin D, Tagliati F, Luchin A, Zatelli MC, Degli Uberti. EC miR-15a and miR-16-1 down-regulation in pituitary adenomas. Journal of Cellular Physiology. 2004;204:280-285. doi: 10.1002/jcp.20282.
Stilling G, Sun Z, Zhang S, Jin L, Righi A, Kovācs G, Korbonits M, Scheithauer BW, Kovacs K, Lloyd RV. MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine. 2010;38(1):67-75.
Minematsu T, Egashira N, Kajiya H, Takei M, Takekoshi S, Itoh Y, Tsukamoto H, Itoh J, Sanno N, Teramoto A, et al. PTTG is a secretory protein in human pituitary adenomas and in mouse pituitary tumor cell lines. Endocrine Pathology. 2007;18:8-15.
Zhu X, Asa SL, Ezzat S. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clinical Cancer Research. 2008;14:1984-1996.

Close metadata